1.
Muhammad Absar, Nawaf Alanazi, Abdulaziz Siyal, Masood Shammas, Amer Mahmood, Sulman Basit, et al. CLINICAL VALIDATION OF ANKRD36 MUTATIONS AS A NOVEL BIOMARKER FOR MONITORING EARLY PROGRESSION AND TIMELY CLINICAL INTERVENTIONS IN BLAST CRISIS CML. J Popl Ther Clin Pharmacol [Internet]. 2022 Feb. 23 [cited 2024 Nov. 18];29(02):311-20. Available from: https://mail.jptcp.com/index.php/jptcp/article/view/4161